2 days Ago
Inovio Pharmaceuticals, Inc. ( NASDAQ: INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference.
So next company we have is exciting, Inovio Pharmaceuticals. I think they're still on track to have the first DNA immunotherapy approved in the US, mRNA gets a lot of attention or has gotten a lot of attention but there's some very differentiating aspects of DNA. I think most recently demonstrated with their DMAb monoclonal antibody durability data that we'll hopefully get into.
But we're happy to have, CEO, Dr. Jacqui Shea; and Dr. Mike Sumner, Chief Medical Officer, here to present the story.
So maybe Jacqui let's -- and Mike start, just briefly review the platform and how it differs from these other platforms like mRNA or viral platforms, maybe how broad you can go with DNA? Jacqui Shea Yes. Great question, Roy. And thanks very much for the invitation, nice to be here today.
So when you think about DNA medicines and RNA medicines, they're both nucleotide based therapies. There are actually quite a lot of differences between the two platforms. So the mRNA molecules are inherently more unstable than DNA.
DNA is much more stable and they're also delivered in different ways. So mRNA requires lipid nanoparticles for delivery and to protect the mRNA from degradation. Whereas with DNA, we use our proprietary delivery systems called CELLECTRA.
So mRNA can be quite dependent on ultracold chain for distribution, DNA being much more stable. We don't require any frozen shipping or storage. And then when you think about the kinds of immune responses that mRNA generates versus the DNA medicines platform, mRNA is very good at generating very high -- ultrahigh levels of.
